Dana H. Gabuzda, MD
Office phone: 617-632-2154
Website: Gabuzda Lab Website
Preferred contact method: office phone
Area of Research
HIV Molecular Biology and Pathogenesis
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
BiographyDr. Gabuzda received her MD from Harvard Medical School in 1983 and did her postgraduate training in internal medicine and neurology at Massachusetts General Hospital. After completing research fellowships at Johns Hopkins University and DFCI, she joined the DFCI faculty in 1991. She is primarily involved in basic laboratory research on HIV replication and disease mechanisms in AIDS.
ResearchHIV Molecular Biology and Pathogenesis
The Gabuzda lab uses genetic, biochemical, metabolomic, systems biology, and computational approaches to study HIV infection and comorbidities including cancer. Research interests include understanding viral, host, and environmental factors that determine clinical outcomes, therapeutic responses, and accelerated aging. Current projects include studies on:
- 1) virus-host interactions during HIV replication and pathogenesis that impact immune control, inflammation, metabolic disorders, and comorbidities
- 2) role of exosomes in cell-cell communication, immune regulation, stress responses, and disease pathophysiology
- 3) mechanisms involved in HIV-associated neurological disorders and accelerated aging
- 4) cancer risk and etiologies in aging populations with HIV
The lab is proficient at bioinformatic, computational, and systems biology approaches including generation, analysis, interpretation, and visualization of large data sets, big data handling, and using bioinformatic software and R programs for data integration, network prediction, pathway analysis, and modeling. The lab also uses machine learning and other computational approaches to model longitudinal trajectories and identify new predictors of clinical outcomes. The long-term goal is gaining multidisciplinary knowledge that leads to progress in personalized medicine for HIV-infected and aging populations.
Complete Publications List: http://www.ncbi.nlm.nih.gov/sites/myncbi/dana.gabuzda.1/collections/47703338/public/
- Yan Z, Shah PK, Amin SB, Samur MK, Huang N, Wang X, Misra V, Ji H, Gabuzda D, Li C.Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. Nucleic Acids Res 2012;40:e135.
- Mukerji J, Olivieri KC, Misra V, Agopian KA, Gabuzda D. Proteomic analysis of HIV-1 Nef cellular binding partners reveals a role for exocyst complex proteins in mediating enhancement of intercellular nanotube formation. Retrovirology 2012;9:33.
- Kamat A, Misra V, Cassol E, Ancuta P, Yan Z, Li C, Morgello S, Gabuzda D. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One 2012;7:e30881.
- Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 2013;13:203.
- Gabuzda D, Yankner BA. Physiology: Inflammation links ageing to the brain. Nature 2013;497:197-8.
- Cassol E, Misra V, Dutta A, Morgello S, Gabuzda D. Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. AIDS 2014;28:1579-91.
- Pery E, Sheehy A, Miranda Nebane N, Misra V, Mankowski MK, Rasmussen L, Lucile White E, Ptak RG, Gabuzda D. Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1. Virology 2015;484:276-87.
- Cassol E, Misra V, Morgello S, Kirk GD, Mehta SH, Gabuzda D. Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression. J Acquir Immune Defic Syndr 2015;69:18-28.
- Pery E, Sheehy A, Nebane NM, Brazier AJ, Misra V, Rajendran KS, Buhrlage SJ, Mankowski MK, Rasmussen L, White EL, Ptak RG, Gabuzda D. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. J Biol Chem 2015;290:10504-17.
- Mukerji SS, Locascio JJ, Misra V, Lorenz DR, Holman A, Dutta A, Penugonda S, Wolinsky SM, Gabuzda D. Lipid Profiles and APOE4 Allele Impact Midlife Cognitive Decline in HIV-Infected Men on Antiretroviral Therapy. Clin Infect Dis 2016 Jul 22. pii: ciw495. [Epub ahead of print]
- Chettimada, Sukrutha, PhD
- Dutta, Anuprya, PhD
- Guha, Debjani, PhD
- Mukerji, Shibani, MD, PhD
- Solomon, Isaac, MD, PhD